LAVAL, QC, April 14 /CNW Telbec/ - Neptune Technologies & Bioressources
Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) provides guidance for the expected
financial results of the fiscal 2009 third quarter and nine-month period ended
February 28, 2009. These results represent the year-end results for its fiscal
year 2009 now ending on February, 28.
Neptune expects total revenues for the three-month period ended February
28, 2009 in the range of $3,400,000 to $3,800,000 compared to $2,875,000 for
the third quarter ended February 29, 2008 representing an increase of 18% to
Total revenues for the nine-month period ended February 28, 2009 are
expected to be in the range of $8,200,000 to $8,600,000 compared to $7,130,000
for the nine-month period ended February 29, 2008. This revenue increase
represents between 15% to 21% growth in the nine-month period ended February
28, 2009 compared to the nine-month period ended February 29, 2008.
Neptune is currently expanding its in-house production capacity to be
completed, as planned, before summer 2009 while the Company continues to
expand its customer base worldwide. Neptune expects revenue growth will be
driven by repeat demand from existing customers and incoming demand from new
customers from North America, Europe and Asia.
The world retail nutraceutical market represents more than $50 billion in
annual sales and the European market, newly accessible to Neptune, accounts
for more than one-third of this market with sales beyond $15 billion with
cholesterol, heart health and mental health having a major impact.(1)
The Company is preparing for the projected incoming demand from Europe
following NKO(R) Novel Food approval. The Company believes that several years
of pre-marketing activities have resulted in substantial marketing visibility
and recognition in Europe.
In that perspective, the Company is negotiating strategic alliances for
high scale production with multinational industrial manufacturing partners to
rapidly secure substantially larger capacity in order to meet repeat and
growing demand from existing and new customers worldwide.
Neptune has achieved several value-creating milestones during fiscal year
NOVEL FOOD and PARNUTS approval granted for NKO(R)
NKO(R) has successfully passed rigorous regulatory review and scrutiny by
all member states of the European Union (EU), which provided a positive
opinion for NKO(R) as a NOVEL FOOD and PARNUTS allowing its commercialization
at a clinically proven effective daily dose in all 27 European countries.
Formation of NeuroBioPharm for neurological applications
Neptune structured part of its pharmaceutical operations into its
subsidiary NeuroBioPharm for cognitive function and neurological disease and
is currently conducting a clinical study for a medical food product with a
Human clinical study demonstrates superior Neptune Krill Oil NKO(R)
NKO(R) achieved a significantly higher bioavailability compared to
successfully marketed nutraceutical and pharmaceutical omega-3 and NKO(R) like
phospholipid formulations supporting the claim of the superiority of Neptune's
Completion of $2.75 million private placement with 10% management
The proceeds from this financing has been invested by Neptune in Acasti
Pharma in order to reach several value-creating development and commercial
milestones within Acasti Pharma's over-the-counter, prescription medical food
and prescription drug programs.
Neptune and Marine Life Sciences enter alliance with Weider Global
Neptune and Marine Life Sciences have functional custom-built
combinations of proprietary marine ingredients, to be commercialized as a
dietary supplement and a new functional food product line by Weider Global
Neptune Krill Oil, NKO(R), enters WALGREENS
Schiff Nutrition International Inc. has launched Schiff(R) MegaRed(TM)
containing Neptune Krill Oil (NKO(R)) in Walgreens, which represents the
largest retail pharmacy chain in the United States with over 6,400 drug stores
Neptune completes up to $8.5 million debt financing with Desjardins Group
The Company expects the funds to be used to improve productivity and
increase production capacity.
Formation of an operating pharmaceutical subsidiary named Acasti Pharma
Neptune structured part of its pharmaceutical operations into its
subsidiary Acasti Pharma to carry out the research, development and
commercialization of active pharmaceutical ingredients for chronic
cardiovascular disease and to partner with pharmaceutical companies.
OmegaGen(R) marketed in Australia
OmegaGen(R) Neptune Krill Oil NKO(R), a complementary medicine, has been
made widely available in Australia at the majority of pharmacy chains
Breakthrough of Schiff(R) MegaRed(TM) in Costco USA
Schiff(R) MegaRed(TM) containing Neptune Krill Oil, NKO(R), has been
listed as a permanent item in Costco in the United States.
Please visit us at our newly designed website at www.neptunebiotech.com.
About Neptune Technologies & Bioressources Inc.
Neptune is the pioneer and leader in marine omega-3 phospholipids, which
are the highest quality Omega-3s available in the market, clinically shown to
be effective in cholesterol management, joint health, inflammation and
cognitive function. Neptune Krill Oil NKO(R) represents the first and only,
clinically proven omega-3 phospholipids exhibiting unmatched safety, purity
and stability. NKO(R) omega-3 marine phospholipids set a new standard of
omega-3 excellence supported by a strong intellectual property portfolio and
multinational regulatory approvals. Neptune pursues market opportunities in
the nutraceutical markets (dietary supplement, functional food) and
pharmaceutical markets (OTC, medical food, Rx) through its subsidiaries Acasti
Pharma for cardiovascular applications and NeuroBioPharm for neurological
NASDAQ does not accept responsibility for the adequacy or accuracy of
this press release. Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of
Statements in this press release that are not statements of historical or
current fact, including statments relating to the Company's expectation
regarding the future performance and marketability of its products, constitute
"forward-looking statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks, uncertainties, and
other unknown factors that could cause the actual results of the Company to be
materially different from historical results or from any future results
expressed or implied by such forward-looking statements. In addition to
statements which explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes," "belief,"
"expects," "intends," "anticipates,"should," "will," or "plans" to be
uncertain and forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that are described
from time to time in the Company's reports filed with the Securities and
Exchange Commission and the Canadian securities commissions.
(1) Industry Canada; International Market Research: Dietary Supplements
For further information:
For further information: Neptune Contact: Toni Rinow, Ph.D., MBA
Corporate Development & Investor Relations, Neptune Technologies &
Bioressources Inc., (450) 687-2262, email@example.com;
www.neptunebiotech.com; Source: Neptune Technologies & Bioressources Inc.